

## **Engagement Report for Clinical Commissioning Policies**

Unique Reference Number	tba
Policy Title	Multiple Sclerosis Management Service for Children
Accountable Commissioner	Bernie Stocks
Clinical Reference Group	Paediatric Neurosciences
Which stakeholders were contacted to be involved in policy development?	MS Society (part of Specification Working Group) MS Trust (part of Specification Working Group) Paediatric Neurosciences CRG – periodic versions shared to comment on (Nov 2015, Oct 2016, plus via Stakeholder testing February 2017) British Paediatric Neurosciences Association (BPNA) (ongoing periodic review for comment inc Stakeholder Testing February 2017) Epilepsy UK (via Stakeholder testing February 2017) Together for Short Lives via Stakeholder testing February 2017) Muscular Dystrophy UK (via Stakeholder testing February 2017) Paediatric Neurosurgery Operational Delivery Networks (via Stakeholder testing February 2017) Metabolic CRG (periodic versions shared to comment on (Nov, Dec 2015, plus via Stakeholder testing February 2017). Royal College of Paediatrics and Child Health (RCPCH) (via Stakeholder testing February 2017). NMO Service
Identify the relevant Royal College or Professional Society to the policy and indicate how	British Paediatric Neurosciences Association – periodic versions shared to comment on RCPCH – copy sent as part of stakeholder testing, was considered by college Representative at February Metabolic CRG meeting

Unique Reference Number	tba
they have been involved	
Which stakeholders have actually been involved?	Sixteen responses were received in total from: West Midlands Neurosciences Network Paediatric Neurosciences CRG Metabolic CRG MS Society MS Trust BPNA Royal College of Physicians Royal College of Paediatrics and Child Health NMO Service (Oxford) Midlands Children's Neurosciences Network Birmingham Women and Childrens NHSFT Nottingham University Hospitals NHS Trust (3) The John Radcliffe Hospital Novartis
Explain reason if there is any difference from previous question	Some consultees did not reply to the consultation invite
Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?	None
How have stakeholders been involved? What engagement methods have been used?	The MS Trust and MS Society have been represented on the Specification Working Group which has involved 1:1 and group teleconferences and emails of draft documents for comment over a period of months. In addition the Paediatric Neurosciences CRG has received and commented on the document on three occasions, the Metabolic CRG has considered the document twice and the British Paediatric Neurosciences Association has received

Unique Reference Number	tba
	and commented on the document on two occasions.
What has happened or changed as a result of their input?	Comments were considered by the clinical members of the SWG and NHS England commissioners, and a number of additions and changes have been made to the specification as part of an iterative development process.
How are stakeholders being kept informed of progress with policy development as a result of their input?	The outcome of consideration of the comments received from the Paediatric Neurosciences CRG has been discussed with the Accountable Commissioner and Clinical Lead. The outcome of consideration of the comments from the MS Trust, MS Society and RCPCH has been fed back to these stakeholders they are in support of the changes made as a consequence.
What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?	Public consultation for 30 days to take place
stakeholder involvement?	